Malignant Solid Tumours

Also known as: Malignant Solid Tumor / Malignant Solid Tumour / Malignant Solid Tumors / Cancer / Neoplasm malignant / Malignant neoplasm NOS / Cancer NOS / Malignant tumor / Malignant tumour / Cancer (NOS) / Malignant neoplasm without specification of site

DrugDrug NameDrug Description
DB14723LarotrectinibLarotrectinib is an orally administered tropomyosin receptor kinase (Trk) inhibitor with demonstrated antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Originally discovered by Array BioPharma, the agent was ultimately licensed to Loxo Oncology in 2013. Larotrectinib is another example of innovative new cancer therapy medications that target key, specific genetic biomarker drivers of cancer rather than particular types of tumors [L4847].
DrugDrug NamePhaseStatusCount
DB06013Aldoxorubicin1Completed1
DB12064BMS-7776071Completed1
DB01101Capecitabine1Completed1
DB14707Cemiplimab1Recruiting1
DB00002Cetuximab1Completed1
DB00531Cyclophosphamide1Completed1
DB11651Dactolisib1Completed1
DB01254Dasatinib1Completed1
DB12021Dinaciclib1Recruiting1
DB00530Erlotinib1Completed1
DB00441Gemcitabine1Completed1
DB01611Hydroxychloroquine1Active Not Recruiting1
DB00762Irinotecan1Active Not Recruiting1
DB12906LY-23347371Completed1
DB09079Nintedanib1Completed1
DB09035Nivolumab1Active Not Recruiting1
DB09035Nivolumab1Completed1
DB09074Olaparib1Completed1
DB09074Olaparib1Recruiting1
DB09037Pembrolizumab1Recruiting1
DB12060RRx-0011Active Not Recruiting2
DB12060RRx-0011Completed1
DB12060RRx-0011Terminated1
DB00877Sirolimus1Completed1
DB01390Sodium bicarbonate1Terminated1
DB00398Sorafenib1Completed1
DB01268Sunitinib1Unknown Status1
DB01030Topotecan1Completed2
DB05294Vandetanib1Completed1
DB00361Vinorelbine1Terminated1
DB02546Vorinostat1Active Not Recruiting1
DB02546Vorinostat1Completed1
DB02546Vorinostat1Terminated1
DB11945Avelumab1 / 2Recruiting1
DB00112Bevacizumab1 / 2Recruiting1
DB00515Cisplatin1 / 2Recruiting1
DB01248Docetaxel1 / 2Recruiting1
DB06486Enzastaurin1 / 2Completed1
DB00530Erlotinib1 / 2Completed1
DB00544Fluorouracil1 / 2Completed1
DB00441Gemcitabine1 / 2Recruiting1
DB00650Leucovorin1 / 2Completed1
DB11596Levoleucovorin1 / 2Completed1
DB09035Nivolumab1 / 2Recruiting2
DB00526Oxaliplatin1 / 2Completed1
DB01229Paclitaxel1 / 2Completed1
DB09037Pembrolizumab1 / 2Active Not Recruiting1
DB09037Pembrolizumab1 / 2Recruiting1
DB00811Ribavirin1 / 2Unknown Status1
DB06026Tivantinib1 / 2Completed1
DB12200Tivantinib1 / 2Completed1
DB00072Trastuzumab1 / 2Recruiting1
DB06205Vorhyaluronidase alfa1 / 2Recruiting1
DB00515Cisplatin2Completed1
DB01248Docetaxel2Completed1
DB00947Fulvestrant2Recruiting1
DB00441Gemcitabine2Completed1
DB05774Necitumumab2Completed1
DB09559Necitumumab2Completed1
DB11828Neratinib2Recruiting1
DB01229Paclitaxel2Active Not Recruiting1
DB01229Paclitaxel2Recruiting1
DB05578Ramucirumab2Active Not Recruiting1
DB05578Ramucirumab2Completed1
DB00072Trastuzumab2Recruiting1
DB00019Pegfilgrastim4Completed1